WO2019100054A1 - Micro-organismes métabolisant la dihydroxyacétone et leurs procédés d'utilisation - Google Patents

Micro-organismes métabolisant la dihydroxyacétone et leurs procédés d'utilisation Download PDF

Info

Publication number
WO2019100054A1
WO2019100054A1 PCT/US2018/061976 US2018061976W WO2019100054A1 WO 2019100054 A1 WO2019100054 A1 WO 2019100054A1 US 2018061976 W US2018061976 W US 2018061976W WO 2019100054 A1 WO2019100054 A1 WO 2019100054A1
Authority
WO
WIPO (PCT)
Prior art keywords
glpf
glda
alss
buda
mgsa
Prior art date
Application number
PCT/US2018/061976
Other languages
English (en)
Inventor
Keelnatham T. Shanmugam
Liang Wang
Diane Sylvie CHAULIAC
Lonnie O'neal Ingram
Mun Su Rhee
Anushadevi PANNEERSELVAM
Original Assignee
University Of Florida Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Florida Research Foundation filed Critical University Of Florida Research Foundation
Publication of WO2019100054A1 publication Critical patent/WO2019100054A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
    • C12P7/04—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic
    • C12P7/06—Ethanol, i.e. non-beverage
    • C12P7/065—Ethanol, i.e. non-beverage with microorganisms other than yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
    • C12P7/04—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic
    • C12P7/16—Butanols
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/44—Polycarboxylic acids
    • C12P7/46—Dicarboxylic acids having four or less carbon atoms, e.g. fumaric acid, maleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/56—Lactic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00—Technologies for the production of fuel of non-fossil origin
    • Y02E50/10—Biofuels, e.g. bio-diesel

Definitions

  • DHA dihydroxyacetone
  • DHA can be catalytically produced from formaldehyde by the formose reaction (Deng et al., 2013; Gehrer et al., 1995; Matsumoto et al., 1984). DHA can be fermented to a number of chemicals and fuels, such as ethanol, butanol, lactate, and succinate, by appropriately engineered microbial biocatalysts (Fig. 1).
  • Formaldehyde is currently industrially produced from methanol and methanol itself is produced from CH 4 (see worldwide website: ihs.com/products/chemical-technology-pep-reviews-formaldehyde-from- natural-gas-1974.html), leading to a chemical process from CH 4 to fermentable sugar, DHA (Fig. 1).
  • Formaldehyde can be produced chemically from C0 2 via methanol as an intermediate (Dong et al., 2017; Kothandaraman et al., 2016).
  • formaldehyde can also be produced biologically from C0 2 with formate as an intermediate (Fig. 1) (Alissandratos & Easton, 2015). Rapid conversion of formaldehyde to DHA and DHA-P can serve as a new pathway for conversion of C0 2 to bio-products.
  • DHA cycle pentose-phosphate dependent pathway
  • Dihydroxyacetone in the cytoplasm is phosphorylated by DHA kinase and/or glycerol kinase and the DHA-3-phosphate that enters glycolysis provides a route for utilization of CH 4 and C0 2 by biological systems.
  • formaldehyde can be produced by several microorganisms, the rate of production may not be high enough to support a biorefinery.
  • Siegel, et al. described a computationally enhanced enzyme, formolase, that converts formaldehyde to DHA (Siegel et al., 2015). However, this pathway is yet to be demonstrated in a microorganism.
  • microorganisms that metabolize DHA provides a cost- effective approach for reducing production cost of biologically produced metabolites. Accordingly, genetically modified microorganisms that can increase the microorganisms’ ability to metabolize DHA as described herein.
  • the genes identified to be associated with the increased metabolism of DHA are ATP- dependent dihydroxyacetone kinase (dhaK), glycerol uptake facilitator ( glpF ), glycerol dehydrogenase ( gldA ), a-acetolactate decarboxylase ( budA ), acetolactate synthase (a/sS), pyruvate formate-lyase (pfIBA ), and methyl glyoxal synthase ( mgsA ).
  • dhaK ATP- dependent dihydroxyacetone kinase
  • glpF glycerol uptake facilitator
  • gldA glycerol dehydrogenase
  • budA a-acetolactate decarboxylase
  • a/sS acetolactate synthase
  • pfIBA pyruvate formate-lyase
  • mgsA methyl glyox
  • the present disclosure provides microorganisms that metabolize DHA, wherein the microorganisms are genetically modified to increase the expression or activity of DhaK protein.
  • the genetic modifications that increase the expression of DhaK include the expression via plasmids, mutations in the genomic DNA of microorganisms that result in the increased expression of DhaK, or mutations in the regulatory region of genes that cause overexpression of DhaK.
  • the microorganisms are genetically modified to inactivate one or more genes selected from glpf, gldA, budA, alsS, pfIBA, and mgsA.
  • the subject present disclosure provides microorganisms, for example, Escherichia coli, that are useful in the production of metabolites of interest by growing the microorganisms in media containing DHA. Accordingly, the materials and methods of the present disclosure can be used to produce metabolites used in a variety of applications.
  • the microorganisms according to the present disclosure have one genetic modification.
  • the genetic modification resulting in the increased expression of DhaK comprises introducing into the microorganism a nucleotide sequence encoding a DhaK.
  • the DhaK is the DhaK from the bacterium Klebsiella oxytoca (SEQ ID NO: 50).
  • the DhaK is encoded by dhaK from the bacterium Klebsiella oxytoca comprises the native promoter and the protein encoding region.
  • the dhaK from the bacterium Klebsiella oxytoca comprising the native promoter and the protein encoding region comprises the sequence of (SEQ ID NO: 51).
  • the DhaK comprises a sequence selected from SEQ ID NOs: 28 to 49.
  • microorganisms comprising one or more genetic modifications inactivating one or more genes encoding: glycerol uptake facilitator (GlpF), methylglyoxal synthase (MgsA), acetolactate decarboxylase (BudA), acetolactate synthase (AlsS), and pyruvate formate-lyase (PfIBA), and glycerol dehydrogenase (GldA).
  • GlpF glycerol uptake facilitator
  • MgsA methylglyoxal synthase
  • BudA acetolactate decarboxylase
  • AlsS acetolactate synthase
  • PfIBA pyruvate formate-lyase
  • GldA glycerol dehydrogenase
  • microorganisms comprising one or more genetic modifications inactivating a combination comprising of genes selected from:
  • budA alsS, pfIBA, and gldA
  • glpF mgsA, budA, alsS, pfIBA, and gldA.
  • microorganisms comprising one or more genetic modifications inactivating a combination consisting of genes selected from:
  • budA alsS, pfIBA, and gldA
  • glpF mgsA, budA, alsS, pfIBA, and gldA.
  • the microorganism is Escherichia coli, Gluconobacter oxydans, Gluconobacter asaii, Achromobacter delmarvae, Achromobacter viscosus, Achromobacter lacticum, Agrobacterium tumefaciens, Agrobacterium radiobacter, Alcaligenes faecalis, Arthrobacter citreus, Arthrobacter tumescens, Arthrobacter paraffineus, Arthrobacter hydrocarboglutamicus, Arthrobacter oxydans, Aureobacterium saperdae, Azotobacter indicus, Brevibacterium ammoniagenes, divaricatum, Brevibacterium lactofermentum, Brevibacterium flavum, Brevibacterium globosum, Brevibacterium fuscum, Brevibacterium etoglutamicum, Brevibacterium helcolum, Brevibacterium pusillum, Brevibacterium testaceum, Brevibacterium rose
  • microorganisms as described herein when cultured in a medium containing DHA, can produce an increased amount of a metabolite compared to the amount of the metabolite produced by the parental microorganism cultured in the medium containing DHA.
  • Described herein are methods of culturing or growing a microorganism in a medium comprising DHA.
  • Culturing or growing as described herein can be under conditions that allow for the production of a metabolite of interest.
  • the culturing or growing can be a batch process, fed- batch process or a continuous process.
  • the culturing or growing can be a fed-batch process and DHA is introduced into the culture medium in a fed-batch manner at a concentration of: 250 mM to 500 mM, 275 mM to 350 mM, about 325 mM, or about 333 mM.
  • Methods as described herein can further comprise recovering the metabolite of interest.
  • compositions comprising a microorganism of as described herein and a medium as described herein.
  • the medium can comprise DHA.
  • Engineered cells as described herein can comprise a microorganism containing therein one or more genetic modifications resulting in an increased expression of ATP-dependent dihydroxyacetone kinase (DhaK), increased activity of DhaK, or both, thereby providing the engineered cell increased DHA metabolism compared to the wild-type non-modified organism.
  • DhaK ATP-dependent dihydroxyacetone kinase
  • the one or more genetic modifications contained therein resulting in increased expression can comprise one or more expression vectors for exogenous expression of one or more recombinant enzymes relating to DHA metabolism, the one or more expression vectors comprising a nucleotide sequence encoding a recombinant DhaK protein.
  • the nucleotide sequence encoding a recombinant DhaK comprises SEQ ID NO: 50.
  • the nucleotide sequence encoding a recombinant DhaK is derived from the bacterium Klebsiella oxytoca and comprises the native promoter and the native protein encoding region.
  • the nucleotide sequence encoding a recombinant DhaK is derived from the bacterium Klebsiella oxytoca and comprises the native promoter and the protein encoding region comprises the sequence of SEQ ID NO: 51.
  • the nucleotide sequence encoding a recombinant DhaK comprises a sequence selected from SEQ ID NOs: 28 to 49.
  • the one or more genetic modifications resulting in increased activity of DhaK comprises inactivating one or more genes encoding: glycerol uptake facilitator (GlpF), methylglyoxal synthase (MgsA), acetolactate decarboxylase (BudA), acetolactate synthase (AlsS), and pyruvate formate-lyase (PfIBA), and glycerol dehydrogenase (GldA).
  • GlpF glycerol uptake facilitator
  • MgsA methylglyoxal synthase
  • BudA acetolactate decarboxylase
  • AlsS acetolactate synthase
  • PfIBA pyruvate formate-lyase
  • GldA glycerol dehydrogenase
  • the one or more genetic modifications resulting in increased activity of DhaK can comprise inactivating:
  • the microorganism of engineered cells as described herein is Escherichia coli, Gluconobacter oxydans, Gluconobacter asaii, Achromobacter delmarvae, Achromobacter viscosus, Achromobacter lacticum, Agrobacterium tumefaciens, Agrobacterium radiobacter, Alcaligenes faecalis, Arthrobacter citreus, Arthrobacter tumescens, Arthrobacter paraffineus, Arthrobacter hydrocarboglutamicus, Arthrobacter oxydans, Aureobacterium saperdae, Azotobacter indicus, Brevibacterium ammoniagenes, divaricatum, Brevibacterium lactofermentum, Brevibacterium flavum, Brevibacterium globosum, Brevibacterium fuscum, Brevibacterium ketoglutamicum, Brevibacterium helcolum, Brevibacterium pusillum, Brevibacterium testaceum, Brevibacter
  • Described herein are methods of metabolizing dihydroxyacetone (DHA), comprising: providing a plurality of engineered cells, each of the plurality being an engineered cell as described herein; providing a medium comprising DHA (or medium and DHA separately then combining the two); and culturing the plurality of engineered cells in the medium comprising DHA to metabolize DHA and produce a DHA metabolite of interest.
  • the culturing is a batch process, fed-batch process, or a continuous process.
  • the culturing can be a fed-batch process and DHA is introduced into the culture medium in a fed-batch manner at a concentration of: 250 mM to 500 mM, 275 mM to 350 mM, about 325 mM, or about 333 mM.
  • Methods as described herein can further comprise isolating the metabolite of interest.
  • kits can comprise one or more microorganisms; and one or more expression vectors comprising one or more recombinant DhaK coding sequences, one or more expression vectors inactivating one or more genes encoding: glycerol uptake facilitator (GlpF), methylglyoxal synthase (MgsA), acetolactate decarboxylase (BudA), acetolactate synthase (AlsS), and pyruvate formate-lyase (PfIBA), and glycerol dehydrogenase (GldA), one or more expression vectors decreasing activity of proteins: glycerol uptake facilitator (GlpF), methylglyoxal synthase (MgsA), acetolactate decarboxylase (BudA), acetolactate synthase (AlsS), and pyruvate formate-lyase (PfI
  • GldA glycerol uptake
  • the one or more one or more recombinant DhaK coding sequences have about 90% to about 100% sequence identify with SEQ ID NOs 28-51.
  • GlpF glycerol uptake facilitator
  • MgsA methylglyoxal synthase
  • BudA acetolactate decarboxylase
  • AlsS acetolactate synthase
  • PfIBA pyruvate formate-lyase
  • GldA glycerol dehydrogenase
  • glpF glpF, mgsA, budA, and pflBA
  • glpF mgsA, budA, and alsS
  • mgsA, budA, alsS, and pflBA mgsA, budA, alsS, and gldA
  • mgsA, budA, pflBA, and gldA mgsA, alsS, pflBA, and gldA;
  • glpF mgs A, budA, alsS, pfIBA, and gldA.
  • the one or more expression vectors decreasing activity of proteins decrease activity of enyzyme products of:
  • glpF mgsA, budA, alsS, pflBA, and gldA.
  • kits can comprise one or more engineered cells as described herein; and a culture medium suitable for growing one or more engineered cells. Kits can further comprise dihydroxyacetone (DHA).
  • DHA dihydroxyacetone
  • Fig. 1 A chemical or biological process for production of DHA from C0 2 or CH 4 and further fermentation of DHA to products of commercial interest.
  • Figs. 2A-2B Fermentative growth of E. coli strain TG1 13 with or without DHA kinase encoding plasmids.
  • Cultures were grown in LB medium supplemented with DHA (10 or 30 g.L -1 ) at 37°C with pH control at 7.0.
  • Figure 2A 1 1 1 mM DHA
  • Figure 2B 333 mM DHA.
  • Fig. 3 Fed-batch fermentation of DHA by E. coli strain TG1 13 (pDC1 17d). Fermentation was started with 333 mM DHA in LB medium at 37°C. At 29 hrs, an additional 333 mM DHA was added to the cultures. pH of the cultures was controlled at 7.0 with 2N KOH.
  • FIGs. 4A-4B Fermentation of glucose or DHA in LB medium by K. variicola at 37°C and pH 7.0.
  • Figure 4A glucose (275 mM);
  • Figure 4B DHA (333 mM).
  • Fig. 5 Fed-batch fermentation of DHA in LB by K. variicola strain LW225. Fermentation was started with 333 mM DHA in LB at 37°C and pH 7.0. At 23, 34 and 46 h, additional 333 mM DHA was added to a total of 1.33 M (120 g.L 1 ). All of the added DHA was fermented at 60 h.
  • FIGs. 6A-6B Fermentation of DHA to succinate or ethanol by engineered E. coli derivatives.
  • Figure 6A Fermentation of DHA in LB by E. coli strain KJ122 (pDC1 17d) to succinate was started with 87 mM DHA at 37°C and pH 7.0. At various times (24, 42.5, 71.5, 93.5 and 145 h), 100 mM DHA was added to the fermentation to a total of 590 mM.
  • Figure 6B Fermentation of DHA in LB by an ethanologenic E. coli strain SE2378 (pDC1 17d) was started with 99 mM DHA at 37°C and pH 7.0. At 21.5 h, an additional 181 mM DHA was added to the fermentation for a total of 280 mM.
  • Fig. 7 Fermentation pathway for Dihydroxyacetone of E. coli.
  • The“X” over the arrows leading to glycerol and acetyl-coA represent deletion of the gldA and pfIB, respectively in the mutant strains.
  • DHA dihydroxyacetone
  • DHA-P dihydroxyacetone-3-phosphate
  • GlpF glycerol uptake facilitator
  • GldA glycerol dehydrogenase
  • DhaD dihydroxyacetone oxidoreductase
  • TPI triose-phosphate isomerase
  • FRD fumarate reductase
  • D-LDH D- lactate dehydrogenase
  • PFI pyruvate formate-lyase
  • ADH alcohol dehydrogenase
  • PTA phosphotransacetylase
  • ACK acetate kinase.
  • Fig. 8 Sensitivity of K. variicola to DHA.
  • Strain LW200 was inoculated into pH- controlled (7.0) fermentations (37°C) with the indicated concentration of DHA in LB. Cell density and lactate concentration were determined during a 48 h period and the highest values are presented.
  • Fig. 9 Metabolic and inhibitory pathways of DHA in E. coli.
  • DHA added to culture medium is transported by glycerol facilitator (GlpF) and by other unidentified transporters. If the concentration of DHA in the medium is higher than the rate of transport, DHA that accumulates at the cell surface interacts with externally exposed components of the cell leading to growth inhibition. Once DHA enters the cell, it is phosphorylated by DHA kinase to non-toxic DHA-phosphate. If the DHA kinase activity is lower than the rate of DHA transport, excess DHA in the cytoplasm interacts with cellular components such as DNA and protein leading to growth inhibition. For rapid growth and fermentation of DHA to a product of choice, a balance among various reactions, transport, kinase level and activity, and ATP availability, needs to exist to overcome the toxicity of DHA.
  • GlpF glycerol facilitator
  • Fig. 10 Inhibition of the growth of E. coli by DHA.
  • Strain TG1 13(pDC1 17d) or LW416 (TG1 13, AglpF, pDC1 17d) was inoculated into pH-controlled (7.0) fermentations (37 °C) with the indicated concentration of DHA in LB. Cell density and lactate concentration were determined during a 48-h period, and the highest values are presented. Reported values for LW416 with 456 mM DHA are from 96-h incubation. Dashed lines indicate TG1 13 (pDC1 17d); solid lines indicate LW416; circles indicate cell density; squares indicate D-lactate titer.
  • Embodiments of the present disclosure will employ, unless otherwise indicated, techniques of chemistry, inorganic chemistry, material science, and the like, which are within the skill of the art. Such techniques are explained fully in the literature.
  • phrases“consisting essentially of or“consists essentially of indicate that the claim encompasses embodiments containing the specified materials or steps and those that do not materially affect the basic and novel characteristic(s) of the claim.
  • ranges are stated in shorthand, so as to avoid having to set out at length and describe each and every value within the range. Any appropriate value within the range can be selected, where appropriate, as the upper value, lower value, or the terminus of the range.
  • a range of 0.1 -1.0 represents the terminal values of 0.1 and 1.0, as well as the intermediate values of 0.2, Q.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, and all intermediate ranges encompassed within 0.1-10, such as 0.2-0.5, 0.2-0.8, 0.7-1.0, etc.
  • a range of 5-10 indicates all the values between 5.0 and 10.0 as well as between 5.00 and 10.00 including the terminal values. Also, when ranges are used herein, combinations and subcombinations of ranges (e.g., subranges within the disclosed range), and the specific embodiments therein, are included.
  • control is an alternative subject or sample used in an experiment for comparison purposes and included to minimize or distinguish the effect of variables other than an independent variable.
  • “overexpressed” or“overexpression” refers to an increased expression level of an RNA or protein product encoded by a gene as compared to the level of expression of the RNA or protein product in a normal or control cell.
  • expression refers to the process by which polynucleotides are transcribed into RNA transcripts. In the context of mRNA and other translated RNA species, “expression” also refers to the process or processes by which the transcribed RNA is subsequently translated into peptides, polypeptides, or proteins.
  • nucleic acid and“polynucleotide” generally refer to a string of at least two base-sugar-phosphate combinations and refers to, among others, single-and double- stranded DNA, DNA that is a mixture of single-and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double- stranded or a mixture of single- and double-stranded regions.
  • polynucleotide as used herein refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA.
  • the strands in such regions may be from the same molecule or from different molecules.
  • the regions may include all of one or more of the molecules, but more typically involve only a region of some of the molecules.
  • One of the molecules of a triple-helical region often is an oligonucleotide.
  • Polynucleotide” and “nucleic acids” also encompasses such chemically, enzymatically or metabolically modified forms of polynucleotides, as well as the chemical forms of DNA and RNA characteristic of viruses and cells, including simple and complex cells, inter alia.
  • the term polynucleotide includes DNAs or RNAs as described above that contain one or more modified bases.
  • DNAs or RNAs comprising unusual bases, such as inosine, or modified bases, such as tritylated bases, to name just two examples are polynucleotides as the term is used herein.
  • “Polynucleotide” and“nucleic acids” also includes PNAs (peptide nucleic acids), phosphorothioates, and other variants of the phosphate backbone of native nucleic acids.
  • Natural nucleic acids have a phosphate backbone, artificial nucleic acids may contain other types of backbones, but contain the same bases.
  • DNAs or RNAs with backbones modified for stability or for other reasons are“nucleic acids” or "polynucleotide” as that term is intended herein.
  • RNA deoxyribonucleic acid
  • DNA deoxyribonucleic acid
  • RNA ribonucleic acid
  • DNA unmodified RNA or DNA or modified RNA or DNA.
  • RNA may be in the form of a tRNA (transfer RNA), snRNA (small nuclear RNA), rRNA (ribosomal RNA), mRNA (messenger RNA), anti-sense RNA, RNAi (RNA interference construct), siRNA (short interfering RNA), or ribozymes.
  • nucleic acid sequence and“oligonucleotide” also encompasses a nucleic acid and polynucleotide as defined above.
  • DNA molecule includes nucleic acids/polynucleotides that are made of DNA.
  • wild-type is the typical form of an organism, variety, strain, gene, protein, or characteristic as it occurs in nature, as distinguished from mutant forms that may result from selective breeding or transformation with a transgene.
  • identity is a relationship between two or more polypeptide or polynucleotide sequences, as determined by comparing the sequences. In the art,“identity” also refers to the degree of sequence relatedness between polypeptide as determined by the match between strings of such sequences. “Identity” can be readily calculated by known methods, including, but not limited to, those described in Computational Molecular Biology, Lesk, A. M., Ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D. I/I/., Ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, A. M., and Griffin, H.
  • heterologous refers to compounds, molecules, nucleotide sequences (including genes), and polypeptide sequences (including peptides and proteins) that are different in both activity (function) and sequence or chemical structure.
  • heterologous can also refer to a gene or gene product that is from a different organism. For example, a human GTP cyclohydrolase or a synthase can be said to be heterologous when expressed in yeast.
  • homologue refers to a polypeptide sequence that shares a threshold level of similarity and/or identity as determined by alignment of matching amino acids. Two or more polypeptides determined to be homologues are said to be homologues. Homology is a qualitative term that describes the relationship between polypeptide sequences that is based upon the quantitative similarity.
  • paralog refers to a homologue produced via gene duplication of a gene.
  • paralogs are homologues that result from divergent evolution from a common ancestral gene.
  • orthologues refers to homologues produced by speciation followed by divergence of sequence but not activity in separate species. When speciation follows duplication and one homologue sorts with one species and the other copy sorts with the other species, subsequent divergence of the duplicated sequence is associated with one or the other species. Such species specific homologues are referred to herein as orthologues.
  • xenologs are homologues resulting from horizontal gene transfer.
  • similarity is a quantitative term that defines the degree of sequence match between two compared polypeptide sequences.
  • progeny As used herein, “cell,” “cell line,” and “cell culture” include progeny. It is also understood that all progeny may not be precisely identical in DNA content, due to deliberate or inadvertent mutations. Variant progeny that have the same function or biological property, as screened for in the originally transformed cell, are included.
  • “culturing” refers to maintaining cells under conditions in which they can proliferate and avoid senescence as a group of cells. “Culturing” can also include conditions in which the cells also or alternatively differentiate.
  • organ refers to any living entity comprised of at least one cell.
  • a living organism can be as simple as, for example, a single isolated eukaryotic cell or cultured cell or cell line, or as complex as a mammal, including a human being, and animals (e.g., vertebrates, amphibians, fish, mammals, e.g., cats, dogs, horses, pigs, cows, sheep, rodents, rabbits, squirrels, bears, primates (e.g., chimpanzees, gorillas, and humans).
  • "Subject” may also be a cell, a population of cells, a tissue, an organ, or an organism, preferably to human and constituents thereof.
  • “gene” refers to a hereditary unit corresponding to a sequence of DNA that occupies a specific location on a chromosome and that contains the genetic instruction for a characteristic(s) or trait(s) in an organism.
  • “synthetic gene” can refer to a recombinant gene comprising one or more coding sequences for a protein of interest, or a synthetically purified protein that is not naturally occurring in its purified state.
  • the term“recombinant” generally refers to a non-naturally occurring nucleic acid, nucleic acid construct, or polypeptide.
  • Such non-naturally occurring nucleic acids may include natural nucleic acids that have been modified, for example that have deletions, substitutions, inversions, insertions, etc., and/or combinations of nucleic acid sequences of different origin that are joined using molecular biology technologies (e.g., a nucleic acid sequences encoding a fusion protein (e.g., a protein or polypeptide formed from the combination of two different proteins or protein fragments), the combination of a nucleic acid encoding a polypeptide to a promoter sequence, where the coding sequence and promoter sequence are from different sources or otherwise do not typically occur together naturally (e.g.
  • Recombinant also refers to the polypeptide encoded by the recombinant nucleic acid.
  • Non-naturally occurring nucleic acids or polypeptides include nucleic acids and polypeptides modified by man.
  • plasmid refers to a non-chromosomal double- stranded DNA sequence including an intact“replicon” such that the plasmid is replicated in a host cell.
  • a vector is used in reference to a vehicle used to introduce an exogenous nucleic acid sequence into a cell.
  • a vector may include a DNA molecule, linear or circular (e.g. plasmids), which includes a segment encoding a polypeptide of interest operatively linked to additional segments that provide for its transcription and translation upon introduction into a host cell or host cell organelles.
  • additional segments may include promoter and terminator sequences, and may also include one or more origins of replication, one or more selectable markers, an enhancer, a polyadenylation signal, etc.
  • Expression vectors are generally derived from yeast or bacterial genomic or plasmid DNA, or viral DNA, or may contain elements of both.
  • operatively linked indicates that the regulatory sequences useful for expression of the coding sequences of a nucleic acid are placed in the nucleic acid molecule in the appropriate positions relative to the coding sequence so as to effect expression of the coding sequence.
  • This same definition can also be applied to the arrangement of coding sequences and transcription control elements (e.g. promoters, enhancers, and termination elements), and/or selectable markers in an expression vector.
  • cDNA refers to a DNA sequence that is complementary to a RNA transcript in a cell. It is a man-made molecule. Typically, cDNA is made in vitro by an enzyme called reverse-transcriptase using RNA transcripts as templates.
  • the term“transfection” refers to the introduction of an exogenous and/or recombinant nucleic acid sequence into the interior of a membrane enclosed space of a living cell, including introduction of the nucleic acid sequence into the cytosol of a cell as well as the interior space of a mitochondria, nucleus, or chloroplast.
  • the nucleic acid may be in the form of naked DNA or RNA, it may be associated with various proteins or regulatory elements (e.g., a promoter and/or signal element), or the nucleic acid may be incorporated into a vector or a chromosome.
  • transformation or“transformed” refers to the introduction of a nucleic acid (e.g., DNA or RNA) into cells in such a way as to allow expression of the coding portions of the introduced nucleic acid.
  • a nucleic acid e.g., DNA or RNA
  • “stable expression,”“stable incorporation,”“stable transfection” and the like refer to the integration of an exogenous gene into the genome of a host cell, which can allow for long term expression of the exogenous gene.
  • transient expression As used herein,“transient expression,”“transient transfection,” and the like refer to the introduction of an exogenous gene into a host cell that does not result in stable incorporation of the gene into the host cell.
  • “chemical” refers to any molecule, compound, particle, or other substance that can be a substrate for an enzyme in the enzymatic pathway described herein and/or a carboxylesterase enzyme or biochemical pathway.
  • A“chemical” can also be used to refer to a metabolite of a carboxylic ester.
  • “chemical” can refer to nucleic acids, proteins, organic compounds, inorganic compounds, metabolites etc.“Chemical” can also refer to the product produced by the carboxylesterase action.
  • biologically coupled refers to the association of or interaction between two or more physically distinct molecules, groups of molecules compounds, organisms, or particles where the association is directly or indirectly mediated between the two or more physically distinct molecules, groups of molecules compounds, organisms or particles via a biologic molecule or compound. This can include direct binding between two biologic molecules and signal transduction pathways.
  • biological communication refers to the communication between two or more molecules, compounds, or objects that is mediated by a biologic molecule or biologic interaction.
  • biological molecule “biomolecule,” and the like refer to any molecule that is present in a living organism and includes without limitation, macromolecules (e.g. proteins, polysaccharides, lipids, and nucleic acids) as well as small molecules (e.g. metabolites and other products produced by a living organism).
  • regulation refers to the control of gene or protein expression or function.
  • promoter refers to the DNA sequence(s) that control or otherwise modify transcription of a gene and can include binding sites for transcription factors, RNA polymerases, and other biomolecules and substances (e.g. inorganic compounds) that can influence transcription of a gene by interaction with the promoter. Typically these sequences are located at the 5’ end of the sense strand of the gene, but can be located anywhere in the genome.
  • “native” refers to the endogenous version of a molecule or compound relative to the host cell or population being described.
  • non-naturally occurring refers to a non-native version of a molecule or compound or non-native expression or presence of a molecule or compound within a host cell or other composition. This can include where a native molecule or compound is influenced to be expressed or present at a different location within a host, at a non-native period of time within a host, or is otherwise in an altered environment, even when considered within the host. Non-limiting examples include where a protein that is expressed only in the nucleus of a cell is expressed in the cytoplasm of the cell or when a protein that is only normally expressed during the embryonic stage of development is expressed during the adult stage.
  • RNA can be translated into protein based on the triplet code where 3 nucleotides represent an amino acid. This term also includes the idea that DNA can be transcribed into RNA molecules with biologic functions, such as ribozymes and interfering RNA species.
  • RNA molecule when a RNA molecule is said to be encoded by a particular nucleotide sequence it is to be understood that this is referring to the transcriptional relationship between the DNA and RNA species in question.
  • encoding nucleotide refers to herein as the nucleotide which can give rise through transcription, and in the case of proteins, translation a functional RNA or protein.
  • codon optimized refers to a codon modification or making modifications to the codons for amino acids in a polypeptide such that they reflect the codon usage bias of the cell type that the polypeptide is expressed in. Modifications to the codons can be made using techniques generally known in the art.
  • the term “metabolite produced by a microorganism” refers to a metabolite of commercial interest. Metabolites that can be produced from the microorganisms of the present disclosure and commercially used depend on the parent microorganism genetically modified to produce the microorganism of the present disclosure. For example, a microorganism producing succinate can be genetically modified according to the present disclosure to produce a microorganism capable producing succinate by metabolizing DHA as a carbon source.
  • the metabolites envisioned to be produced by the microorganism of interest include ethanol, succinate, malate, lactate, acetate, and formate. Additional examples of metabolites that can be produced by a microorganism are well known to a person of ordinary skill in the art and such embodiments are within the purview of the present disclosure.
  • the phrase“parental microorganism” refers to the microorganism to which the genetic modifications according to the present disclosure are performed to produce the DHA metabolizing microorganism of the present disclosure. Accordingly, the characteristics of DHA metabolizing microorganisms of the present disclosure are represented in relation to the parental microorganisms. For example, a parental microorganism may metabolize DHA to a product of interest to a certain level; however, when genetically modified according to the present disclosure, the resultant microorganism metabolizes DHA to the product of interest at a higher level compared to that of the parental microorganism.
  • the wild-type E. coli is genetically modified according to the present disclosure to produce an E. coli that metabolizes DHA to a product of interest
  • the wild-type E. coli is the parental microorganism of the resultant DHA metabolizing E. coli.
  • the E. coli strain containing the initial genetic modification is the parental strain of the resultant DHA metabolizing E. coli.
  • microorganism refers to organisms recognized in the art as “microorganisms”. Microorganisms contemplated in the present disclosure include bacteria, filamentous fungi, and yeast. Additional examples of microorganism that can be used according to the present disclosure are well known to a person of ordinary skill in the art and such embodiments are within the purview of the present disclosure.
  • A“native gene” or“an endogenous gene” is a gene that is naturally found in a host microorganism; whereas, an “exogenous gene” is a gene introduced into a host microorganism and which was obtained from a microorganism other the host microorganism.
  • a“native promoter” or“endogenous promoter” is a promoter that is naturally found in a host microorganism.
  • “exogenous promoter” or“heterologous promoter” is a promoter introduced into a host microorganism via a genetic construct and which was obtained from a microorganism different from host microorganism.
  • non-italicized abbreviations as used herein refer to the corresponding protein; whereas italicized abbreviations used herein refer to the corresponding gene.
  • the term“BudA” refers to a-acetolactate decarboxylase protein
  • the term“budA” refers to the gene encoding the a-acetolactate decarboxylase protein.
  • coding sequence or“coding region” refers to the portions] of a gene’s DNA or RNA that codes for protein.
  • a DhaK coding sequence can be the portion of a dhaK gene that codes for the DhaK protein.
  • a DhaK coding sequence can comprise the exons of a dhaK gene spliced together in a recombinant DNA sequence or vector.
  • DHA can be produced from an abundant source of natural gas by chemical processes with formaldehyde as an intermediate. Carbon dioxide, a by-product of various industries including ethanol/butanol biorefineries, can also be converted to formaldehyde and then to DHA. DHA, upon entry into a cell and phosphorylation to DHA-3-phosphate enters the glycolytic pathway, and can be fermented to several products. However, DHA is inhibitory to microbes due to its chemical interaction with cellular components.
  • the present disclosure provides microorganisms comprising one or more genetic modifications resulting in an increased expression or catalytic activity of DhaK.
  • the one or more genetic modifications according to the present disclosure produce microorganisms that exhibit, compared to the parental microorganisms, increased metabolism of DHA.
  • DhaK Non-limiting examples of DhaK that can be used in the present disclosure are provided by proteins identified by the UniProt entries: A0A1 S7RJ83 (SEQ ID NO: 29), M1 PGD2 (SEQ ID NO: 30), A0A0P0ADK4 (SEQ ID NO: 31), N1 LHI3 (SEQ ID NO: 32), A0A0D6SX59 (SEQ ID NO: 33), A0A0M2NGK1 (SEQ ID NO: 34), A0A0G8CNG7 (SEQ ID NO: 35), A0A0G8F707 (SEQ ID NO: 36), A0A1X6QHI3 (SEQ ID NO: 37), A0A1X6PRC2 (SEQ ID NO: 38), A0A1 S8G149 (SEQ ID NO: 39), A0A1 R4IR08 (SEQ ID NO: 40), L0DGU5 (SEQ ID NO: 41), A0A1 W7M7M6 (SEQ ID NO:
  • dhakor DhaK coding sequences can be derived from a parent sequence of organisms and/or sequences as described herein. Sequences derived from a parent sequence can maintain at least the sequences necessary to express a functional protein (for example the sequence for the active site of the enzyme), and a sequence derived from a parent sequence can maintain about 50% to about 100% sequence identity with the parental gene or parental coding sequence, about 60% to about 90% sequence identity with the parental gene or parental coding sequence, or about 70% to about 80% sequence identity with the parental gene or parental coding sequence. It would be within the skill of the art for a skilled artisan to derive and express a sequence of interest for microorganisms, methods, and kits as described herein for the same purpose of microorganisms, methods, and kits as described herein.
  • the genetic modification resulting in the increased expression of DhaK comprises introducing into the microorganism a nucleotide sequence, for example, a DNA or RNA sequence, comprising a dhaK, synthetic dhaK, coding sequence for a DhaK, or synthetic coding sequence for a DhaK.
  • a dhaK, synthetic dhaK, or DhaK coding sequence present in a DNA vector introduced into a microorganism is identical to the dhaK or DhaK coding sequence present in the genome of the microorganism, i.e., the DNA vector provides extra copies of the endogenous dhaK or DhaK coding sequence.
  • a dhaK, synthetic dhaK, , synthetic dhaK, coding sequence for a DhaK, or DhaK coding sequence present in a DNA vector is different from the dhaK or DhaK coding sequence present in the genome of the microorganism, i.e., the DNA vector provides an exogenous homolog of the dhaK or DhaK coding sequence present in the genome of the microorganism.
  • a dhaK or DhaK coding sequence is not present in the genome of the microorganism into which a dhaK or DhaK coding sequence in a DNA vector is introduced, i.e., the DNA sequence is the only source of a dhaK or DhaK coding sequence in the microorganism.
  • a dhaK gene or DhaK coding sequence in a DNA vector introduced into a microorganism is the dhaK gene or DhaK coding sequence from the bacterium Klebsiella oxytoca (SEQ ID NO: 50).
  • a dhaK or DhaK coding sequence in a DNA vector introduced into a microorganism is the dhaK comprising the native promoter as well as the protein encoding region (i.e. coding sequence) from the bacterium Klebsiella oxytoca.
  • An example of such DNA vector comprising the native promoter as well as the protein encoding region from the bacterium Klebsiella oxytoca is given by (SEQ ID NO: 51).
  • a dhaK gene or DhaK coding sequence in a DNA vector introduced into a microorganism is a synthetic recombinant dhaK gene or DhaK coding sequence from the bacterium Klebsiella oxytoca (SEQ ID NO: 50).
  • any of the genes encoding DhaK proteins identified above with the Uniprot entries can also be used without or with the corresponding native promoters.
  • a skilled artisan can identify the corresponding gene or protein coding sequence, including the corresponding promoter sequence (or otherwise suitable promoter sequence), and prepare and use the appropriate DNA vector.
  • DNA vectors comprising the dhaK or DhaK coding sequence includes a plasmid, cosmid, yeast artificial chromosome (YAC), 2-micron DNA. Additional examples of DNA vectors suitable for the expression of a gene of interest in a microorganism are well known to a person of ordinary skill in the art and such embodiments are within the purview of the present disclosure.
  • An example of a typical DNA vector or artificial/synthetic DNA vector suitable for the expression of a gene of interest into a microorganism can comprise an origin of replication, a promoter which can drive the expression of the gene, synthetic gene, or coding sequence, one or more selectable markers, and one or more restriction enzyme cleavage sites for cloning the gene of interest into the DNA vector.
  • the promoter can be an inducible promoter or a constitutive promoter, and can be a promotor that is specific for the microorganisms into which the DNA vector is introduced into.
  • the selectable markers can be an antibiotic resistance gene or a gene providing for a missing biochemical function in the microorganism.
  • the DNA vector comprising the dhaK, synthetic dhaK, synthetic dhaK, coding sequence for a DhaK, or DhaK coding sequence is incorporated into the genome of the microorganism.
  • the DNA vector comprising the dhaK, synthtitc dhaK, synthetic dhaK, coding sequence for a DhaK, or DhaK coding sequence is present as an extra-genomic genetic material.
  • the microorganism is a bacterium and the DNA vector is a plasmid carrying the dhaK, synthetic dhaK, DhaK coding sequence, or synthetic DhaK coding sequence.
  • the microorganism is a bacterium and the DNA vector is an artificial/synthetic plasmid carrying the dhaK, synthetic dhaK, DhaK coding sequence, or synthetic DhaK coding sequence
  • the present disclosure provides microorganisms comprising one or more genetic modifications resulting in the increased expression or activity of DhaK and further comprising one or more genetic modifications inactivating one or more genes encoding: glycerol uptake facilitator (GlpF), methyl glyoxal synthase (MgsA), acetolactate decarboxylase (BudA), acetolactate synthase (AlsS), and pyruvate formate-lyase (PfIBA), and glycerol dehydrogenase (GldA).
  • GlpF glycerol uptake facilitator
  • MgsA methyl glyoxal synthase
  • BudA acetolactate decarboxylase
  • AlsS acetolactate synthase
  • PfIBA pyruvate formate-lyase
  • GldA glycerol dehydrogenase
  • Homologs of glpF, mgsA, budA, alsS, pfIBA, and gldA in various bacteria are well known and a person of ordinary skill in the art can determine appropriate homologs of these genes or proteins to be used in particular embodiments. Such embodiments are within the purview of this present disclosure.
  • genes glpF, mgsA, budA, alsS, pfIBA, and gldA are inactivated.
  • any combination of two, three, four, or five genes from glpF, mgsA, budA, alsS, pfIBA, and gldA can be inactivated in the microorganisms of the present disclosure. Such combinations include:
  • budA alsS, pfIBA, and gldA ;
  • glpF mgsA, budA, alsS, pfIBA, and gldA as well as any combination thereof.
  • Microorganisms produced according to the instant disclosure can have one or more genes inactivated by various methods known in the art.
  • Deletion/inactivation of a gene indicates that the genetic modification of the gene results in inactivation of the enzymatic activity of the polypeptide produced by the gene.
  • a gene can be inactivated by the introduction into the gene of insertions, deletions, random mutations, frameshift mutations, point mutations, insertion of one or more stop codons or a combination thereof.
  • certain aspects of the present disclosure provide insertion of at least one stop codon (e.g., one to ten or more stop codons) into the gene.
  • Some aspects of the present disclosure provide for the insertion or deletion of 1 , 2, 4, 5, 7, 8, 10, 1 1 , 13, 14, 16, 17, 19, 20, 22, 23, 25, 26, 28, 29 or more bases to introduce a frameshift mutation into a gene.
  • Yet other embodiments of the subject application provide for the introduction of one or more point mutations (e.g., 1 to 30 or more) within a gene while other aspects of the present disclosure provide for the total or complete deletion of a gene. Mutations and/or deletions in the promoter region of a gene resulting in the inactivation of the gene can also be performed.
  • metabolic pathways are inactivated by the inactivation of the enzymatic activity of the polypeptide(s) encoded by the inactivated gene(s).
  • inactivation of genes as described herein can also be accomplished by other means, such as siRNA/shRNA knockdown (which can be accomplished using expression vectors encoding siRNA, for example, tailored to a gene of interest), increased degradation of RNA transcripts, blocking of RNA transcription, or increased degradation of protein.
  • siRNA/shRNA knockdown which can be accomplished using expression vectors encoding siRNA, for example, tailored to a gene of interest
  • increased degradation of RNA transcripts for example, tailored to a gene of interest
  • blocking of RNA transcription or increased degradation of protein.
  • the present disclosure provides microorganisms, wherein the parental microorganisms produce metabolites of interest using a carbon source different from DHA.
  • metabolites of interest include ethanol, butyric acid, lactic acid, and succinic acid. Additional embodiments of metabolites of interest that can be produced by microorganisms are known to a skilled artisan and such embodiments are within the purview of the present disclosure.
  • Such parental microorganisms that produce metabolites of interest are genetically modified according to the present disclosure, particularly, by overexpressing or increasing catalytic activity of DhaK, and optionally, further inactivating one or more genes from glpF, mgsA, budA, alsS, pfIBA, and gldA, the resultant microorganisms produce the metabolite of interest using DHA as a carbon source.
  • Non-limiting examples of the genetically modified bacterial microorganisms according to the subject present disclosure include Escherichia coli, Klebsiella spp., K. oxytoca, K. variicola, Gluconobacter oxydans, Gluconobacter asaii, Achromobacter delmarvae, Achromobacter viscosus, Achromobacter lacticum, Agrobacterium tumefaciens, Agrobacterium radiobacter, Alcaligenes faecalis, Arthrobacter citreus, Arthrobacter tumescens, Arthrobacter paraffineus, Arthrobacter hydrocarboglutamicus, Arthrobacter oxydans, Aureobacterium saperdae, Azotobacter indicus, Brevibacterium ammoniagenes, Brevibacterium lactofermentum, Brevibacterium flavum, Brevibacterium globosum, Brevibacterium fuscum, Brevibacterium ketoglutamicum, Brevibacterium
  • the microorganism of the present disclosure is E. coli or Klebsiella spp. , particularly, K. oxytoca or K. variicola.
  • the microorganisms of the subject present disclosure can be employed in production of metabolites of interest using growth media containing DHA.
  • the DHA metabolizing microorganisms of the present disclosure are metabolically evolved for desirable characteristics, for example, synthesis of metabolites of interest.
  • a further embodiment of the present disclosure provides a method of culturing or growing a microorganism of the present disclosure in a medium containing DHA under conditions that allow the production of a metabolite of interest.
  • the methods further comprise recovering, purifying, or otherwise isolating the metabolite[s] of interest.
  • the culturing or growing can be performed in a batch process, a fed batch process, or a continuous process.
  • DHA can be introduced into the culture medium in a fed-batch manner at a DHA concentration at the feeding points from 250 mM to 500 mM, preferably, between 275 mM to 350 mM, and more preferably about 325 mM, and even more preferably, about 333 mM.
  • Methods of producing different culture/growth media and conditions that allow culturing/growing of the microorganisms of interest are well known to a person of ordinary skill in the art and such embodiments are within the purview of the present disclosure.
  • Methods of recovering products of interest from culture/growth media are also well known in the art and such embodiments are within the purview of the present disclosure.
  • fermentation of DHA to D-lactate by E. coli strain TG1 13 was inefficient and growth was inhibited by 30 g. L 1 DHA.
  • An ATP-dependent DHA kinase from Klebsiella oxytoca (pDC1 17d) permitted growth of strain TG1 13 in a medium with 30 g.L 1 DHA and in a fed-batch fermentation, the D-lactate titer of TG1 13 (pDC1 17d) was 580 ⁇ 21 mM at a yield of 0.92 g.g -1 DHA fermented.
  • Klebsiella variicola strain LW225 with a higher glucose flux, compared to E.
  • DHA can also be fermented to succinic acid and ethanol, demonstrating the potential of converting CH 4 and C0 2 to value-added chemicals and fuels by a combination of chemical/biological processes.
  • Methods as described herein can comprise providing a plurality of microorganisms or engineered cells as described herein (a homologous plurality or heterologous plurality); providing a medium comprising DHA; and culturing the plurality of engineered cells in the medium comprising DHA to metabolize DHA and produce a DHA metabolite of interest.
  • the culturing can be a batch process, fed-batch process, or a continuous process.
  • the culturing can be a fed-batch process and DHA is introduced into the culture medium in a fed-batch manner at a concentration of: 250 mM to 500 mM, 275 mM to 350 mM, about 325 mM, or about 333 mM.
  • Methods as described herein can comprise isolating the metabolite of interest by a method as known in the art (for example filtering, HPLC, evaporation, distillation, and the like).
  • metabolites of interest are lactate, L-lactate, D-lactate, succinate, ethanol, and butanol.
  • metabolites of interest are lactate, L-lactate, and D-lactate.
  • a metabolite of interest is succinate.
  • metabolites of interest are ethanol and butanol.
  • kits can comprise one or more microorganism and one or more expression vectors, the one or more expression vectors encoding a DhaK protein, inactivating one or more genes encoding: glycerol uptake facilitator (GlpF), methylglyoxal synthase (MgsA), acetolactate decarboxylase (BudA), acetolactate synthase (AlsS), and pyruvate formate-lyase (PfIBA), and glycerol dehydrogenase (GldA), one or more expression vectors decreasing activity of proteins: glycerol uptake facilitator (GlpF), methylglyoxal synthase (MgsA), acetolactate decarboxylase (BudA), acetolactate synthase (AlsS), and pyruvate formate-lyase (PfIBA), and glycerol uptake facilitator (GlpF), methylgly
  • kits comprising one or more microorganisms or engineered cells as described herein and culture medium.
  • the kit can further comprise DHA, either as a component of the medium or separate component to be mixed with the medium by the user.
  • Bacterial strains, plasmids, and primers are listed in Tables 1 , 2 and 3, respectively. Bacterial cultures were grown in LB medium described previously (Patel et al., 2006). Mineral salts medium was AM1 medium (Martinez et al., 2007).
  • Low-phosphate medium was a modification of a medium described by Jin and Lin (Jin & Lin, 1984) and contained, MOPS (50 mM), KH2PO4 (1 mM), KCI (40 mM), NaCI (34 mM), (NH 4 ) 2 S0 4 (15 mM), MgS0 4 .7H 2 0 (0.8 mM), casamino acids (1 g.L 1 ), trace mineral solution from AM 1 medium (1 ml.L 1 ) and required amount of DHA. Ampicillin (100 mg.L 1 ), Kanamycin (50 mg.L 1 ), X-Gal (25 mg.L 1 ) and IPTG (5 mM) were added to the media as needed for selection.
  • Ampicillin concentration was increased to 1.5 g.L 1 for Klebsiella spp.
  • Anaerobic cultures were grown in 13 x 100 mm screw cap tubes filled to the top. Fermentations were in 500 ml vessels with 250 ml of medium as described previously with pH control at 37°C (Beall et al., 1991). Fermentations started aerobically due to the air in the gas phase and the cultures were mixed by a magnetic stirrer (200 RPM) for base addition.
  • E. coli strains TG1 13, KJ122, and SE2378 were described previously (Grabar et al., 2006; Jantama et al., 2008; and Kim et al., 2007).
  • Strain LW290 is a derivative of strain TG1 13 with a deletion o gldA, which eliminates glycerol dehydrogenase. This strain was constructed using the method described by Datsenko and Wanner (Datsenko & Wanner, 2000). The primers used to amplify the kanamycin resistance gene flanked by FRT sequences and the 5’- and 3’-ends of gldA were 353 and 354.
  • strain LW290 kanamycin-resistant transformants
  • Strain LW410 was derived from strain TG1 13 and carries a 572 bp internal deletion of glpF and was constructed using the method of Datsenko and Wanner (Datsenko & Wanner, 2000). Details of construction of strain LW410 are presented below.
  • E.coli strain LW290 For construction of E.coli strain LW290, a AgldA derivative of strain TG1 13 primers 353 and 354 were used to amplify the kanamycin-resistance gene flanked by FRT sequences and the 5' and 3' ends of gldA. The PCR-amplified product was electroporated into strain TG1 13, and kanamycin-resistant transformants were selected (strain LW290). This strain carries a deletion of 1 ,012 bp of DNA within the gldA.
  • E. coli strain LW410 a derivative of strain TG1 13, carries a deletion of glpF encoding glycerol facilitator.
  • PCR-primers 451 and 452 were used to amplify the entire coding region of glpF from the genome of E. coli strain MG 1655 and the amplified fragment was cloned into plasmid vector pCR2.1-TOPO (plasmid pLW79).
  • plasmid pLW79 as template and primers 453 and 454
  • the glpF flanking DNA and the plasmid backbone were PCR amplified.
  • This linear DNA lacking a 572 bp internal fragment of glpF was ligated with a PCR product that carries a tetracycline resistance gene cassette (tef) flanked by FRT-sequences from plasmid pLOI2065 (primers 455 and 456) (plasmid pLW80).
  • tef tetracycline resistance gene cassette
  • a linear fragment generated from plasmid pLW80 using primers 451 and 452 that contains the tet gene flanked by FRT and glpF was electroporated into strain TG1 13 and the tetracycline resistant transformants were selected.
  • K. variicola strain LW225 a mutant of wild type strain AC1 lacking butanediol synthesis pathway enzymes, a-acetolactate decarboxylase ( budA ) and acetolactate synthase (a/sS), and pyruvate formate-lyase ( pfIBA ), was constructed to eliminate side reactions at the pyruvate node for production of D-lactate. Details of strain construction are presented below.
  • Strain LW225 carries a deletion of the genes budA, alsS, and pfIBA encoding acetolactate decarboxylase, acetolactate synthase, and pyruvate formate-lyase, respectively, to eliminate side reactions at the pyruvate node.
  • a 1 ,500 bp budA-alsS gene fragment was amplified from K. variicola wild type strain AC1 genomic DNA with primers bupro070910 F and bud070910 R2.
  • the amplified product after confirmation by sequencing the DNA, was ligated into plasmid vector pUC19 that was hydrolyzed with HinCII (pMSR-141).
  • the kanamycin resistance gene cassette with FRT was obtained from plasmid pLOI251 1 after Smal digestion (1 ,228 bp).
  • a 758 bp internal fragment of the budA-alsS gene fragment was removed from plasmid pMSR-141 after Blpl and Bglll hydrolysis and the ends are filled in using the Klenow fragment of DNA polymerase (Klenow fill-in).
  • the kanamycin resistance cassette with FRT fragment was inserted at this site (pMSR-141-Km).
  • a PCR product containing buc/A-kan-FRT (1 ,953bp) was generated with the primer pair bupro070910 F, bud070910 R2.
  • This buc/A-kan-FRT linear DNA fragment (1 ,953 bp) was introduced into strain AC1 by electroporation (18KV/cm, 25 pF, 200W using Bio-Rad Gene Pulser XCell; Hercules, CA) and transformants were selected on LB-agar with kanamycin (50 mg.L 1 ). Competent cells of AC1 were prepared by washing a mid-exponential phase culture grown in LB 3 times with 10 % glycerol. AC1- buc/A-FRT-kan-FRT (strain MR900) was confirmed by its fermentation profile.
  • plasmid pCP20 was introduced into strain MR900 and transformants were selected on LB-agar with ampicillin (500 mg.L 1 ) and chloramphenicol (40 mg.L 1 ) at 30°C. After incubation of transformants at 42°C, kanamycin sensitive strain MR901 was obtained.
  • a 3, 127 bp pfIBA gene fragment was amplified using strain AC1 genomic DNA as the template and primers newpfIBA F and newpfIBA R. The amplified product was ligated into plasmid vector pUC19 after hydrolysis by EcoRI and Hindlll (pMSR-144).
  • Kanamycin resistance gene cassette with FRT was ligated into plasmid pMSR-144 after hydrolysis with Nrul that removed 2,356 bp pfIBA DNA (pMSR-144-Km).
  • a 3,635 bp fragment from pKD46 after hydrolysis with EcoRV and Stul was ligated with a 1 ,998 bp pfIBA- km fragment obtained after amplifying the DNA from plasmid pMSR-144-Km with primers newpfIBA F and newpfIBA R (pMSR-145).
  • This temperature sensitive plasmid, pMSR-145 was introduced into strain MR901 and selected on LB-agar with kanamycin (50 mg.L 1 ) at 30°C. After incubation of transformants at 42°C to eliminate the plasmid, mutant strains that lacked PFL activity were identified by their fermentation profile (strain MR902). Based on PCR amplification of remaining pfl DNA in these PFL strains, a pfIBA deletion mutant was identified and the kanamycin-resistance cassette was removed using FLP-recombinase. The (budA-alsS)- FRT, ApfIBA- FRT derivative of strain AC1 was maintained as strain LW225.
  • TA-cloning of DNA inserts was performed according to Manufacturer’s instructions with 4 pi of gel-purified PCR-product, 1 pi salt solution and 1 mI of commercial pCR2.1-TOPO vector.
  • the cloning reaction was allowed to proceed for 30 min at room temperature before transforming 2 pL of cloning reaction into CaCI 2 competent E. coli Top10 (Invitrogen) or StellarTM cells (Clontech).
  • Transformants were selected on LB-agar supplemented with kanamycin, X-Gal and IPTG. White colonies were screened by colony PCR and the DNA insert was confirmed by DNA Sequencing.
  • Plasmid pDC4 carries the dhaKLM operon (PEP-dependent DHA kinase) from E. coli with the native promoter in plasmid vector pTOPO.
  • the dhaKLM DNA (4,283 bp) was amplified from E. coli MG1655 genomic DNA using primers 15 and 16 and cloned into plasmid vector pCR2.1-TOPO (TA-cloning). It includes a 553 bp DNA upstream of the dhaK start codon (ATG) and a 557 bp DNA sequence downstream of the dhaM stop codon of the dhaKLM operon.
  • Plasmid pDC1 14cL that carries the dhaK from K. oxytoca ( dhaK K o ) (ATP-dependent DHA kinase from Klebsiella oxytoca strain M5A1) was constructed using TA-cloning and blue- white selection.
  • a 2354 bp DNA containing the dhaK K o M5A1 was amplified by PCR with the genomic DNA as template and primers 783 and 784. Orientation of the inserted DNA and DNA sequence were verified by PCR and sequencing, respectively.
  • Plasmid pDC1 17d carries the dhaK with its native promoter from K. oxytoca strain M5A1 in plasmid vector pBR322.
  • Plasmid pDC1 17d was constructed using CPEC method (Quan & Tian, 201 1). Plasmid pBR322 was linearized by PCR using primers 803 and 418 without the tet coding region. The dhaK K o Insert (2,589 bp) was amplified from plasmid pDC114cL using primers 804 and 805 and this includes a 235 bp native DNA sequence upstream of the start codon of the dhaK gene. This amplified fragment was inserted into linearized plasmid pBR322 DNA and transformed into E. coli strain Top10. Ampicillin-resistant and tetracycline sensitive transformants were screened by colony PCR and an appropriate plasmid was confirmed by DNA sequencing.
  • dhaK K o was amplified by PCR from plasmid pDC1 17d and inserted into pTrc99a for expression from its tac promoter.
  • a tetracycline resistance gene was inserted into pTrc99a (pLW60) for transformation into K. variicola due to its innate resistance for ampicillin.
  • the tetracycline-resistance gene was amplified by PCR from pLOI2065 using primers, 377 and 378.
  • the 1 ,875 bp fragment was inserted into a PCR amplified pTrc99a (primers 375 and 376; 3,121 bp backbone of the plasmid without the ampicillin resistance gene) by the CPEC method.
  • the resulting plasmid pLW60 served as the vector for cloning a promoterless dhaK K o from plasmid pDC1 17d.
  • Plasmid pLW60 DNA was amplified by PCR using primers 175 and 176 to generate a 4,916 bp fragment with the ends at the MCS of the plasmid pLW60.
  • a promoterless dhaK was amplified by PCR from plasmid pDC1 17d using primers 393 and 394. After digestion of the linearized plasmid vector fragment by Ncol and the dhaK fragment by Ncol and Eco53KI, the two fragments were ligated and transformed into E. coli Top10 (plasmid pLW63). Tetracycline- resistant transformants were selected and the plasmid was verified by PCR and DNA sequencing.
  • DHA kinase activity was determined in crude extracts of cultures grown in 250 ml of LB + DHA (30 g.L 1 ) in fermenters with pH control (7.0) or under aerobic conditions (2.8 L Fernbach flask; 200 RPM) at 37°C to mid-exponential phase of growth. Cells harvested by centrifugation at 4,200 x g for 10 min at 4°C were washed once with 20 ml of HEPES buffer (50 mM; pH 7.5). Cells collected by centrifugation (5,900 x g; 5 min) were resuspended in 2 ml of HEPES buffer.
  • DHA kinase was assayed using ATP or PEP as phosphate donor in a coupled assay as described previously (Gutknecht et al., 2001 ; Johnson et al., 1984).
  • One ml assay mixture for ATP-dependent activity contained HEPES buffer (50 mM; pH 7,5), MgCI 2 (2.55 mM), NADH (0.25 mM), ATP or PEP (1 mM), glycerol-3-phosphate dehydrogenase (rabbit muscle, 1.7 units; Sigma-Aldrich) and cell extract.
  • Initial rate of oxidation of NADH after addition of DHA (1 mM) was determined in the coupled reaction at 340 nm.
  • One unit of enzyme activity is one pmole. min -1 mg protein -1 .
  • Organic acids, ethanol, and DHA were determined using an Agilent (1200) HPLC equipped with dual detectors (UV and refractive index, in series) and a BioRad Aminex HPX- 87H column (45°C; 4 mM H 2 S0 4 as the mobile phase, 0.4 ml. min -1 flow rate) (Underwood et al., 2002).
  • Optical purity of lactic acid was determined using an Agilent HPLC (1090) equipped with Chirex 3126(D)-penicillamine column (150 x 4.6 mm; Phenomenex, Torrance, CA) and variable wavelength detector. The eluent was 2 mM CuS0 4 at 0.6 ml. min -1 (Chauliac et al., 2015).
  • E. coli produces acetate, ethanol, lactate, formate, H 2 , C0 2 , and small amount of succinate as fermentation products (Fig. 7).
  • DHA is not in the glucose fermentation pathway, it is an intermediate of glycerol metabolism in E. coli especially during anaerobic condition (Gonzalez et al., 2008).
  • DHA produced by glycerol dehydrogenase (gldA) is phosphorylated to DHA-P by a PEP- dependent kinase encoded by dhaKLM that is not associated with transport.
  • DHA kinase was reported to be very low during aerobic growth and increased during 0 2 -Iimitation condition in glycerol- grown cells (Durnin et al., 2009) and thus limiting the glycerol-DHA-DHA- P pathway to anaerobic growth condition.
  • Dihydroxyacetone-3-phosphate an intermediate of glycolysis, is expected to yield the same fermentation products as seen with glucose fermentation (Fig. 7).
  • DHA added to the medium is transported by a facilitated diffusion channel (GlpF). In E. coli and other enteric bacteria, GlpF helps transport glycerol in an energy-independent manner.
  • DHA-P Upon phosphorylation, DHA-P enters the glycolysis pathway and is converted to pyruvate with associated ATP and NADH production.
  • transport and phosphorylation Fermentation of two DHA molecules to one each of acetate and ethanol would yield a net 3 ATPs while fermentation to two lactates results in a net yield of 2ATPs.
  • These ATP yields are the same as that of glucose (2 DHA equivalents) fermentation by this bacterium. This shows that anaerobic growth of E. coli with DHA as a fermentable C-source is not constrained energetically or by redox balance.
  • Wild type E. coli (B, ATCC1 1303; C, ATCC8739; K-12, W31 10 and W, ATCC9637) did not grow with DHA as a carbon source in mineral salts medium under aerobic condition. This was expected apparently due to the very low level of DHA kinase in aerobically grown cells (Durnin et al., 2009). However, similar results were also obtained under anaerobic growth condition in DHA-mineral salts medium. DHA can interact with medium components such as phosphate and generate methylglyoxal, a highly reactive growth inhibitor (Riddle & Lorenz, 1968; Riddle & Lorenz, 1973).
  • strain TG1 13 carries a deletion of mgsA encoding methylglyoxal synthase that catalyzes DHA-P dependent methylglyoxal synthesis and thus eliminating production of this inhibitor by the bacterium from DHA-P.
  • E. coli strain TG1 13 was grown in rich medium with DHA (1 1 1 mM; 10 g.L 1 ). Strain TG1 13 grew in this medium utilizing the nutrients in LB but fermented DHA at a very low level (Figs. 2A-2B, Table 4). About 40 mM DHA was consumed during the first 24 hours and the D-LA yield was 0.66 g.g 1 of consumed DHA. Since there are only two steps between medium DHA and the glycolytic intermediate DHA-P, and the DHA transport is apparently facilitated diffusion, the rate-limiting step is apparently DHA kinase level in the cell.
  • strain TG1 13 (pDC4) grew to a higher cell density and fermented almost all of the 1 1 1 mM DHA added to the LB medium (Table 4; Figs. 2A-2B) although the DHA kinase activity of this culture at midexponential phase of growth was not different from the value of strain TG1 13 without the plasmid (Table 5). The reason for this difference in fermentation of DHA (1 1 1 mM) by the two cultures with comparable DHA kinase activity is not apparent.
  • the rate of transport of DHA may be higher than the rate of conversion to DHA-P by the low DHA kinase activity (about 0.1 unit). This imbalance in the transport and phosphorylation could lead to a higher DHA pool in the cytoplasm triggering production of inhibitory compounds, as seen by accumulation of brown colored compounds in the medium as well as potential direct interaction of DHA with cellular components (Maillard reaction) (Petersen et a!., 2004).
  • Fermentations were in LB medium with the indicated concentration of DHA at pH 7.0 and 37°C. Culture pH was controlled by automatic addition of 2N KOH. The highest cell density in 24 hour fermentations is reported. The amount of DHA removed and D-lactate produced were determined after 24 h fermentations. Lactate yield is g.g -1 of DHA consumed.
  • Plasmid pDC4 carries E. coli dhaKLM encoding PEP-dependent DHA-kinase.
  • Plasmid pDd 17d carries K. oxytoca dhaK encoding an ATP-dependent DHA-kinase.
  • Plasmid pLW63 carries the K. oxytoca dhaK with trc promoter.
  • DHA kinase from K. pneumoniae supported fermentative growth of E. coli in glycerol medium (Sprenger ef a/., 1989). Since strain TG1 13 (pDC4) with PEP-dependent DHA kinase failed to grow at 30 g.L -1 DHA, a gene encoding ATP-dependent DHA kinase was cloned with its native promoter from K. oxutoca strain M5A1 ( dhaK plasmid pDC1 17d) and introduced into strain TG1 13.
  • a higher level of a phosphate donor may also be required to rapidly remove DHA as DHA-P and to mitigate its inhibitory effect on cells.
  • ATP-dependent DHA kinase is suitable here, since conversion of DHA to pyruvate generates two ATPs, while the same set of reactions may generate only one PEP.
  • This two fold-higher level of phosphate donors (ATPs) in the cytoplasm can support higher DHA kinase activity and can offset the inhibitory effect of the higher DHA concentration in the medium.
  • strain TG1 13 (pDC1 17d) produced 580 ⁇ 21 mM D-lactate (52 ⁇ 1.9 g.L -1 ) in 55 hours after an initial lag of about 10 h (Fig. 3).
  • the average volumetric productivity of D-lactate for this culture over a 34 h period was 1.24 g.L -1 h -1 . This value is about 70% of the volumetric productivity reported for strain TG1 13 with glucose in mineral salts medium (Grabar et al., 2006).
  • the lactate yield was 0.94 g.g -1 DHA fermented.
  • Strain TG1 13 (pDC1 17d) also produced very low but detectable amounts of glycerol (27 ⁇ 5 mM), especially during late stationary phase of growth, catalyzed by glycerol dehydrogenase operating in the reverse direction. Deletion of gldA (strain LW290) eliminated glycerol production during DHA fermentation.
  • strain TG1 13 is known to ferment 0.67 M glucose to higher than 1 M lactate in mineral salts medium in about 48 h (Grabar et al., 2006). Declining specific productivity of the aging culture may account for this low titer. Further increase in the DHA kinase level and/or glycolytic flux to raise the ATP level in the cell to support higher kinase activity may be needed to reach the D-lactate titer of strain TG1 13 on glucose.
  • Glucose flux of a homolactate producing derivative of strain AC1 , strain MR902 was calculated to be 5.9 ⁇ 1.6 (g.h -1 g cells -1 ) when grown in LB medium with glucose and this value increased when strain MR902 was grown in mineral salts medium (7.2 ⁇ 0.0.9 g.h -1 g cells -1 ).
  • Average volumetric productivity of D-lactate for strain MR902 was 4.4 g.L -1 .h -1 in rich medium. These values are about twice the productivity for a lactate producing E. coli grown under similar conditions with glucose (Zhou et al., 2006a; Zhou et al., 2006b).
  • strain LW225 had a higher glucose flux, the growth rate of this strain in DHA containing medium was lower than that of an LB-glucose culture (Figs. 4A-4B). Fermentative growth rate of the culture with glucose was 0.84 ir 1 compared to a m value of 0.25 ir 1 for a DHA culture. Specific productivity of lactate with glucose was 5.4 g.ir 1 .gcells 1 while the specific productivity with DHA as C-source was about 35% of the glucose value (1.9 g.h 1 .g cells 1 ). These results suggest that strain LW225 also has a limiting step in DHA utilization, most probably at the DHA-kinase activity, as seen with E. coli strain TG1 13.
  • K. varicola fermented 30 g. L 1 DHA using the native DHA kinase(s) (Figs. 2A-2B and 4A-4B). Even with this higher level of DHA kinase activity K. variicola was unable to grow when the DHA concentration was increased to above 300 mM (Fig. 8) as seen with E. coli TG1 13(pDC1 17d). This inhibition is apparently due to an imbalance between the transport of DHA into the cytoplasm and the ability of the cell to provide ATP/PEP at a rate needed to detoxify DHA by conversion to DHA-P. Due to this growth inhibition by higher concentrations of DHA, strain LW225 fermentations were run in fed-batch mode (Fig. 5).
  • DHA can be readily fermented to D-lactate either by E. coli strain TG1 13 (pDC1 17d) or by K. variicola strain LW225 under appropriate fermentation condition.
  • a reduction in the rate of transport of DHA to match the flux rate of intermediary metabolism and supply of ATP/PEP could overcome the toxicity of DHA while also improving energy balance and D-lactate productivity (Fig. 9).
  • DHA is inhibitory to growth and fermentation of E. coli
  • a rate-limiting step was identified as the activity of DHA kinase.
  • DHA was fermented by E. coli and K. variicola to D-lactic acid.
  • E. coli was fermented by E. coli and K. variicola to D-lactic acid.
  • E. coli was fermented to succinic acid or ethanol, as needed (Table 6). Further metabolic evolution of these microbial biocatalysts is anticipated to increase product titer, yield and productivity.
  • glpF was deleted from the chromosome of TG1 13(pDC1 17d).
  • Deleting glpF strain LW416), and thus eliminating one of the DHA transporters, increased DHA tolerance to about 450 mM, compared with a tolerance of 333 mM DHA for the glpF+ parent with the ATP-dependent DHA kinase (Fig. 10).
  • strain LW416 grew and fermented DHA to D-lactate at about the same rate up to about 350 mM DHA.
  • TG1 13 did not grow, while the glpF mutant grew but at a rate that was about 30% of the value of the 333- mMDHA culture.
  • the final cell density of the 450-mM DHA culture was about 60% of the 333-mM DHA culture. Due to the lower cell density, the average volumetric productivity of D-lactate of the 450-mM DHA culture was about 30% of the same culture with 350 mM DHA (1 .4 g-L-Th-1 ).
  • Embodiments of the present disclosure will employ, unless otherwise indicated, techniques of separating, testing, and constructing materials, which are within the skill of the art. Such techniques are explained fully in the literature.
  • Methylglyoxal bypass identified as source of chiral contamination in L(+) and D(-)-lactate fermentations by recombinant Escherichia coli.
  • Heller KB Lin EC, Wilson TH. 1980.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Selon certains aspects, l'invention concerne des micro-organismes comprenant des modifications génétiques conduisant à une expression ou une activité accrue de la dihydroxyacétone kinase (DhaK) dépendante de l'ATP. Les micro-organismes peut en outre comprendre une ou plusieurs modifications génétiques inactivant un ou plusieurs gènes codant pour : le facilitateur d'absorption de glycérol (GlpF), la méthylglyoxal synthase (MgsA), l'acétolactate décarboxylase (BudA), l'acétolactate synthase (AlsS) et la pyruvate formate-lyase (PflBA) et la glycérol déshydrogénase (GldA). Selon la présente invention, lorsqu'ils sont cultivés dans un milieu contenant du DHA, les micro-organismes produisent une quantité accrue d'un métabolite par rapport à la quantité du métabolite produite par les microorganismes parents. L'invention concerne également des procédés de culture ou de croissance de micro-organismes décrits dans la description, dans des milieux comprenant du DHA et, éventuellement, de récupération des métabolites d'intérêt.
PCT/US2018/061976 2017-11-20 2018-11-20 Micro-organismes métabolisant la dihydroxyacétone et leurs procédés d'utilisation WO2019100054A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762588589P 2017-11-20 2017-11-20
US62/588,589 2017-11-20

Publications (1)

Publication Number Publication Date
WO2019100054A1 true WO2019100054A1 (fr) 2019-05-23

Family

ID=66539131

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/061976 WO2019100054A1 (fr) 2017-11-20 2018-11-20 Micro-organismes métabolisant la dihydroxyacétone et leurs procédés d'utilisation

Country Status (1)

Country Link
WO (1) WO2019100054A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111411062A (zh) * 2020-05-07 2020-07-14 广东省农业科学院植物保护研究所 一株抗生链霉菌及其代谢产物的制备以及其在抗病菌方面的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090155869A1 (en) * 2006-12-01 2009-06-18 Gevo, Inc. Engineered microorganisms for producing n-butanol and related methods
WO2013146557A1 (fr) * 2012-03-29 2013-10-03 Mitsui Chemicals, Inc. Biocatalyseurs permettant de produire de l'acide d-lactique à partir du glycérol
WO2014015210A2 (fr) * 2012-07-20 2014-01-23 Glycos Biotechnologies, Inc. Micro-organismes et procédés de conversion de glycérol en isoprène
US20150176032A1 (en) * 2011-11-30 2015-06-25 Dsm Ip Assets B.V. Yeast strains engineered to produce ethanol from acetic acid and glycerol
WO2018114762A1 (fr) * 2016-12-23 2018-06-28 Dsm Ip Assets B.V. Production améliorée d'éthanol sans glycérol

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090155869A1 (en) * 2006-12-01 2009-06-18 Gevo, Inc. Engineered microorganisms for producing n-butanol and related methods
US20150176032A1 (en) * 2011-11-30 2015-06-25 Dsm Ip Assets B.V. Yeast strains engineered to produce ethanol from acetic acid and glycerol
WO2013146557A1 (fr) * 2012-03-29 2013-10-03 Mitsui Chemicals, Inc. Biocatalyseurs permettant de produire de l'acide d-lactique à partir du glycérol
WO2014015210A2 (fr) * 2012-07-20 2014-01-23 Glycos Biotechnologies, Inc. Micro-organismes et procédés de conversion de glycérol en isoprène
WO2018114762A1 (fr) * 2016-12-23 2018-06-28 Dsm Ip Assets B.V. Production améliorée d'éthanol sans glycérol

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
SANDERS, OL ET AL.: "Antimonite Is Accumulated by the Glycerol Facilitator GIpF in Escherichia coli", JOURNAL OF BACTERIOLOGY, vol. 179, no. 10, May 1997 (1997-05-01), pages 3365 - 3367, XP55611575 *
WANG, L ET AL.: "Fermentation of dihydroxyacetone by engineered Escherichia coli and Klebsiella variicola to products", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCE, vol. 115, no. 17, 9 April 2018 (2018-04-09), pages 4381 - 4386, XP55611578 *
YU , Z ET AL., COMPLETE GENOME SEQUENCE OF KLEBSIELLA SP. STRAIN M5AL PRODUCING A BROADER SET OF CARBOHYDRATE-ACTIVE ENZYMES, 13 April 2017 (2017-04-13), pages 1, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/nucleotide/CP020657.1> [retrieved on 20190115] *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111411062A (zh) * 2020-05-07 2020-07-14 广东省农业科学院植物保护研究所 一株抗生链霉菌及其代谢产物的制备以及其在抗病菌方面的应用
CN111411062B (zh) * 2020-05-07 2021-10-01 广东省农业科学院植物保护研究所 一株抗生链霉菌及其代谢产物的制备以及其在抗病菌方面的应用

Similar Documents

Publication Publication Date Title
KR101711308B1 (ko) 석시네이트 생성을 위한 경로의 엔지니어링
ES2401339T3 (es) Materiales y métodos para producción eficiente de ácido láctico
US8778656B2 (en) Organic acid production in microorganisms by combined reductive and oxidative tricaboxylic acid cylce pathways
JP6302471B2 (ja) 組換え微生物およびその使用
AU2011373671B2 (en) Fermentation of glycerol to organic acids
JP6879976B2 (ja) 低ｐＨ条件下での発酵による有機酸の生産
US20090155869A1 (en) Engineered microorganisms for producing n-butanol and related methods
EP3030649B1 (fr) Procédé de production d&#39;acide succinique utilisant la diffusion facilitée pour l&#39;importation de sucre
BRPI0809400A2 (pt) Materiais e métodos para a produção eficiente de succinato e malato
WO2008119009A2 (fr) Matériaux et procédés pour une production efficace d&#39;alanine
CN105899664A (zh) 用于精细化学品的改进生产的重组微生物
CN108350040A (zh) 用于精细化学品的改进生产的重组微生物
JP2017534268A (ja) 有用産物の生産のための改変微生物および方法
WO2019100054A1 (fr) Micro-organismes métabolisant la dihydroxyacétone et leurs procédés d&#39;utilisation
US8563283B2 (en) Strains of Escherichia coli modified by metabolic engineering to produce chemical compounds from hydrolyzed lignocellulose, pentoses, hexoses and other carbon sources
WO2017223025A1 (fr) Escherichia coli modifiée pour la production d&#39;acide butyrique
WO2014202838A1 (fr) Procédés pour produire du styrène et micro-organismes génétiquement modifiés associés à ceux-ci
WO2017123692A1 (fr) Micro-organismes résistants à des produits secondaires non volatils issus d&#39;un hydrolysat acide d&#39;une biomasse lignocellulosique
US20220213515A1 (en) Method for producing 2-methyl-butyric acid by bacterial fermentation
CN117946950A (zh) 一种新的生产2-羟基异戊酸的脱氢酶及2-羟基异戊酸工程菌的构建和应用
Wood Kien Trung Tran, Toshinari Maeda &

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18878375

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 18878375

Country of ref document: EP

Kind code of ref document: A1